pSTAT3/pSTAT5 Signaling Patterns in Molecularly Defined Subsets of Myeloproliferative Neoplasms

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders.
• BCR/ABL1-negative MPNs are driven by mutations in JAK2, CALR, or MPL.
• These mutations are known to activate JAK/STAT signaling pathways.

Purpose of the Study:

• To characterize JAK/STAT signaling patterns in molecularly defined subsets of BCR/ABL1-negative MPNs.
• To investigate the correlation between specific MPN mutations and the activation of STAT3 and STAT5.
• To explore signaling differences in MPNs lacking common mutations.

Main Methods:

• Immunohistochemistry was used to detect phosphorylated STAT3 (pSTAT3) and phosphorylated STAT5 (pSTAT5).
• Analysis included 30 BCR/ABL1-negative, nonpolycythemia vera MPN patients.
• Patients were stratified based on JAK2 V617F, MPL, and CALR mutation status.

Main Results:

• pSTAT5 nuclear staining in megakaryocytes was significantly associated with JAK2 V617F mutations compared to CALR mutations (P=0.009).
• Erythroid pSTAT5 staining was exclusively observed in "triple-negative" (TN) MPN cases (lacking JAK2, MPL, CALR mutations) (P=0.006).
• Two TN cases also showed pSTAT5 nuclear staining in megakaryocytes, suggesting alternative signaling mechanisms.

Conclusions:

• Distinct STAT signaling patterns correlate with specific mutations in MPNs, indicating divergent signaling events.
• pSTAT5 activation in triple-negative MPN suggests the involvement of unknown molecular abnormalities in disease pathogenesis.
• Understanding these distinct signaling pathways may elucidate biological and prognostic differences among MPN molecular subsets.